[1] Luke C PT, Roder D. Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population. Asian Pac J Cancer Prev ,2010,11(6):1479-1485.
[2] McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int,2006,26(9):1047-1053.
[3] 王磊超, 王志鑫, 冯义康, 等. 基于SEER数据库肝内胆管恶性肿瘤的Nomogram模型建立与验证. 现代预防医学,2022,49(14):2510-2516.
[4] 濮天, 方强, 陈子祥, 等. 肝内胆管癌发病机制及治疗相关进展. 中华消化外科杂志, 2020,19(6):697-702.
[5] Yan W, Wang X, Liu T, et al. Expression of endoplasmic reticulum oxidoreductase 1-α in cholangiocarcinoma tissues and its effects on the proliferation and migration of cholangiocarcinoma cells. Cancer Manag Res, 2019,11:6727-6739.
[6] Wang L, Zhu H, Zhao Y, et al. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience. J Transl Med, 2020,18(1):273.
[7] Yang R, Wang D, Han S, et al. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs. Int J Biol Sci, 2022,18(1):43-64.
[8] Sapisochin G, Ivanics T, Subramanian V, et al. Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: A review of the general principles. Int J Surg, 2020,82:77-81.
[9] Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol, 2020,17(9):557-588.
[10] Zhang XF, Bagante F, Chakedis J, et al. Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. J Gastrointest Surg ,2017,21(11):1841-1850.
[11] Si A, Li J, Yang Z, et al. Impact of Anatomical Versus Non-anatomical Liver Resection on Short- and Long-Term Outcomes for Patients with Intrahepatic Cholangiocarcinoma. Ann Surg Oncol, 2019;26(6):1841-1850.
[12] Zhang XF, Dong DH, Weiss M, et al. Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. Ann Surg, 2021,274(6):e1187-e1195.
[13] Hong JC, Duffy JP, Petrowsky H, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg, 2011,146(6):683-689.
[14] Lunsford KE, Javle M, Gaber AO, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma-Authors' reply. Lancet Gastroenterol Hepatol, 2018,3(8):529-530.
[15] Takahashi K, Obeid J, Burmeister CS, et al. Intrahepatic Cholangiocarcinoma in the Liver Explant After Liver Transplantation: Histological Differentiation and Prognosis. Ann Transpl, 2016,21:208-215.
[16] Boerner T, Drill E, Pak LM, Nguyen B, et al. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021,74(3):1429-1444.
[17] Massard C, Michiels S, Ferté C, et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. Cancer Discov, 2017,7(6):586-595.
[18] Lowery MA, Burris HA, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol, 2019,4(9):711-720.
[19] Philip PA, Mahoney MR, Allmer C, et al. Phase II Study of Erlotinib in Patients With Advanced Biliary Cancer. J Clin Oncol, 2006,24(19):3069-3074.
[20] Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol, 2010,11(12):1142-1148.
[21] Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol, 2014;15(8):819-828.
[22] Kalyukina M, Yosaatmadja Y, Middleditch MJ, et al. TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure. ChemMedChem, 2019,14(4):494-500.
[23] Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol, 2021,32(7):881-895.
[24] Di Costanzo GG, Tortora R, Iodice L, et al. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig Liver Dis. 2012,44(9):788-792.
[25] Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med, 2018,24(5):541-550.
[26] Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma-evolving concepts and therapeutic strategies. Nat Rev Clin Oncol, 2017,15(2):95-111.
[27] Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New Engl J Med, 2010,362(14):1273-1281.
[28] Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer, 2010,103(4):469-474.
[29] Gairing SJ, Thol F, Müller L, et al. The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. J Clin Med, 2021,10(12):2732.
[30] Massani M, Bonariol L, Stecca T. Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review. J Clin Med, 2021,10(12):2552.
[31] Shao F, Qi W, Meng FT, et al. Role of palliative radiotherapy in unresectable intrahepatic cholangiocarcinoma: population-based analysis with propensity score matching. Cancer Manag Res, 2018,10:1497-1506.
[32] Bisello S, Camilletti A, Bertini F, et al. Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review. Mol Clin Oncol, 2021,15(2):152.
[33] 王静,彭昕. 三叶青提取物诱导人肝内胆管癌HCCC-9810细胞凋亡的研究. 中国药师, 2015,18(7):1081-1085.
[34] 宋鑫华. 甘草香豆素预防和治疗肝癌的作用及机制研究. 中国农业大学 2018. |
